@AsuAlbert @DrGauravNarula @smbenlazar @bagalbp @hkJain_kmc @lingarajnayak @MSDiazC @conde_estevez Two doses of rituximab to six cycles of R-CHOP did not improve outcome in patients with aggressive B cell lymphomas and a fast metabolic treatment response.😜
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. #lymphoma #lymsm https://t.co/Ot
RT @Lymphoma_Papers: Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results…
RT @Lymphoma_Papers: Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results…
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial | SpringerLink https://t.co/gmbU5
RT @Lymphoma_Papers: Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results…
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial. #lymphoma #lymsm https://t.co/Ot